Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Natus Medical Inc Reaffirms FY, Q1 2013 Guidance


Thursday, 28 Feb 2013 07:00am EST 

Natus Medical Inc reiterated financial guidance for fiscal 2013 and expects to report revenue in the range of $362-$367 million and non-GAAP earnings per share of $0.81 to $0.84. For the first quarter of 2013, the Company expects to report revenue in the range of $83-$85 million and non-GAAP earnings per share of $0.09 to $0.10. The revenue and non-GAAP earnings per share guidance include the impact of the acquisition of the Grass Technologies Product Group. The guidance does not give effect to the impact of any other potential future acquisitions. The Company's non-GAAP earnings per share guidance excludes charges for amortization expense associated with intangible assets from prior acquisitions and the Grass Technologies acquisition, which the Company expects to be approximately $6.4 million and $1.6 million for the full year and first quarter 2013, respectively, and which the Company expects will reduce GAAP earnings per share by approximately $0.14 and $0.03 for the respective periods. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $362 million and EPS of $0.83 for fiscal 2013; and revenue of $84 million and EPS of $0.09 for the first quarter of 2013. 

Company Quote

28.77
-0.63 -2.14%
31 Jul 2014